Systematic review: persistence and severity in gastro-oesophageal reflux disease
- PMID: 18637097
- DOI: 10.1111/j.1365-2036.2008.03804.x
Systematic review: persistence and severity in gastro-oesophageal reflux disease
Abstract
Background: Management strategies for gastro-oesophageal reflux disease (GERD) are often inconsistent with the proposition that it is a persistent or chronic disease.
Aim: To determine the persistence of reflux symptoms and complications associated with GERD.
Methods: Systematic searches of Medline and EMBASE.
Results: In longitudinal studies, 65% (95% CI 54-75%) of patients with complicated GERD and 70% (95% CI 57-83%) of patients with 'defined' GERD had persistent disease at follow-up, whereas 34% (95% CI 27-40%) with infrequent or mild reflux symptoms at baseline had persistent symptoms. Clinical trials of maintenance treatment for at least 6 months after healing of oesophagitis reported mean relapse rates of 75% (95% CI 68-82%) in patients taking placebo and 28% (95% CI 21-35%) in those taking proton pump inhibitors. Retrospective studies reported that 34-41% of individuals with GERD recalled experiencing their symptoms for >10 years. The prevalence of GERD is high (10-20%), whereas the incidence is low (4.5-19.6 cases per 1000 person-years), suggesting that GERD is likely to persist for at least 18 years.
Conclusions: Individuals with GERD have persistent reflux symptoms that merit management as a chronic disease; infrequent reflux symptoms are less likely to be chronic and may respond to different management strategies.
Similar articles
-
Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.Cochrane Database Syst Rev. 2006 Jul 19;(3):CD002095. doi: 10.1002/14651858.CD002095.pub3. Cochrane Database Syst Rev. 2006. Update in: Cochrane Database Syst Rev. 2010 Nov 10;(11):CD002095. doi: 10.1002/14651858.CD002095.pub4. PMID: 16855986 Updated.
-
Cisapride treatment for gastro-oesophageal reflux in children.Cochrane Database Syst Rev. 2003;(4):CD002300. doi: 10.1002/14651858.CD002300. Cochrane Database Syst Rev. 2003. Update in: Cochrane Database Syst Rev. 2010 Apr 14;(4):CD002300. doi: 10.1002/14651858.CD002300.pub2. PMID: 14583950 Updated.
-
Cisapride treatment for gastro-oesophageal reflux in children.Cochrane Database Syst Rev. 2002;(3):CD002300. doi: 10.1002/14651858.CD002300. Cochrane Database Syst Rev. 2002. Update in: Cochrane Database Syst Rev. 2003;(4):CD002300. doi: 10.1002/14651858.CD002300. PMID: 12137654 Updated.
-
Cisapride treatment for gastro-oesophageal reflux in children.Cochrane Database Syst Rev. 2000;(3):CD002300. doi: 10.1002/14651858.CD002300. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2002;(3):CD002300. doi: 10.1002/14651858.CD002300. PMID: 10908549 Updated.
-
Feed thickener for infants up to six months of age with gastro-oesophageal reflux.Cochrane Database Syst Rev. 2017 Dec 5;12(12):CD003211. doi: 10.1002/14651858.CD003211.pub2. Cochrane Database Syst Rev. 2017. PMID: 29207214 Free PMC article.
Cited by
-
Maintenance therapy of gastroesophageal reflux disease.Clin J Gastroenterol. 2010 Apr;3(2):61-8. doi: 10.1007/s12328-010-0139-z. Epub 2010 Feb 19. Clin J Gastroenterol. 2010. PMID: 26189996
-
Gestational age at birth and risk of gastric acid-related disorders in young adulthood.Ann Epidemiol. 2012 Apr;22(4):233-8. doi: 10.1016/j.annepidem.2012.02.006. Epub 2012 Mar 3. Ann Epidemiol. 2012. PMID: 22382080 Free PMC article.
-
Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement?Dig Dis Sci. 2010 Dec;55(12):3415-22. doi: 10.1007/s10620-010-1209-2. Epub 2010 Apr 17. Dig Dis Sci. 2010. PMID: 20397047
-
Drug treatment strategies for erosive esophagitis in adults: a narrative review.Transl Gastroenterol Hepatol. 2025 Jul 23;10:54. doi: 10.21037/tgh-24-168. eCollection 2025. Transl Gastroenterol Hepatol. 2025. PMID: 40755734 Free PMC article. Review.
-
Follow-up study of vonoprazan maintenance therapy for reflux esophagitis: A 96-week evaluation in patients with PPI-refractory disease.Biomed Rep. 2025 Jul 30;23(4):160. doi: 10.3892/br.2025.2038. eCollection 2025 Oct. Biomed Rep. 2025. PMID: 40777627 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical